TY - JOUR
T1 - Guía de práctica clínica para el diagnóstico y tratamiento de la distrofia muscular de Duchenne. Sociedad Peruana de Neurología. Versión Corta
AU - Martínez-Esteban, Peggy Carol
AU - Guillén-Pinto, Daniel
AU - Duran Padrós, Alfredo Alfonso
AU - Koc-Gonzales, Daniel
AU - Flores-Bravo, Julio
AU - Méndez-Dávalos, Carlos
AU - Suyo-Suyo-Suyo, Caroll
AU - Espíritu-Rojas, Elizabeth R.
AU - Caballero-Bedón, Nathaly
AU - Celis-García, Luis E.
AU - Chávez-Pasco, Vilma Giulliana
AU - Granados-Guibovich, Katia
AU - Graña-Espinoza, Jessica Milagros
AU - Alva-Diaz, Carlos
N1 - Publisher Copyright:
Copyright © 2022 Via Medica.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Objective: to provide evidence-based clinical recommendations for the diagnosis and treatment of Duchenne Muscular Dystrophy. Methods: a guideline development group (GEG) was formed that included specialized physicians in the fields of neurology, neuropediatrics, genetics, and methodology. The GEG asked eight clinical questions to be answered by recommendations in this clinical practice guidelines (CPG). We conducted a systematic search and - when deemed relevant - primary studies in Medline, Scopus, and the Cochrane Controlled Register of Trials during 2021 were reviewed. Evidence was selected to answer each of the clinical questions posed. Certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. In periodic work meetings, the GEG used the GRADE methodology to review the evidence and formulate recommendations, points of good clinical practice, and a diagnosis and treatment flowchart. Results: this CPG addressed eight clinical questions, divided into three topics: screening, diagnosis, and treatment. Based on these questions, fifteen recommendations were formulated (10 strong, 5 conditional) and 11 points for good clinical practice. Conclusion: this paper summarizes the methodology and evidence-based conclusions of the CPG for the diagnosis and treatment of Duchenne muscular dystrophy.
AB - Objective: to provide evidence-based clinical recommendations for the diagnosis and treatment of Duchenne Muscular Dystrophy. Methods: a guideline development group (GEG) was formed that included specialized physicians in the fields of neurology, neuropediatrics, genetics, and methodology. The GEG asked eight clinical questions to be answered by recommendations in this clinical practice guidelines (CPG). We conducted a systematic search and - when deemed relevant - primary studies in Medline, Scopus, and the Cochrane Controlled Register of Trials during 2021 were reviewed. Evidence was selected to answer each of the clinical questions posed. Certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. In periodic work meetings, the GEG used the GRADE methodology to review the evidence and formulate recommendations, points of good clinical practice, and a diagnosis and treatment flowchart. Results: this CPG addressed eight clinical questions, divided into three topics: screening, diagnosis, and treatment. Based on these questions, fifteen recommendations were formulated (10 strong, 5 conditional) and 11 points for good clinical practice. Conclusion: this paper summarizes the methodology and evidence-based conclusions of the CPG for the diagnosis and treatment of Duchenne muscular dystrophy.
KW - Evidence-Based Medicine
KW - GRADE Approach
KW - Muscular Dystrophies
KW - Muscular Dystrophy, Duchenne
KW - Practice Guideline
UR - http://www.scopus.com/inward/record.url?scp=85182301472&partnerID=8YFLogxK
U2 - 10.35663/amp.2022.392.2376
DO - 10.35663/amp.2022.392.2376
M3 - Artículo
AN - SCOPUS:85182301472
SN - 1018-8800
VL - 39
SP - 205
EP - 215
JO - Acta Medica Peruana
JF - Acta Medica Peruana
IS - 2
ER -